Background: and Purpose The relationship between thrombus histology and long-term stroke patient outcomes remains unexplored. We aimed to determine whether the histological characteristics of thrombi are associated with long-term outcomes in stroke patients and to identify the thrombus features linked to these outcomes. Methods: This retrospective multicenter cohort study included 512 patients with ischemic stroke who underwent endovascular thrombectomy between July 2017 and July 2023. Patients were followed up for long-term major adverse cardiovascular events occurrence. Thrombus histology was assessed using immunohistochemistry, including the proportion of fibrin, red blood cells, and platelets, as well as the distribution patterns categorized as layered, erythrocytic, diffuse platelet, and mixed. Results: During a median follow-up of 38.1 months, 164 patients experienced major adverse cardiovascular events, with an incidence rate of 3.02 per 100 person-years. Major adverse cardiovascular events occurrence was associated with the diffuse platelet pattern and proportion of platelets and red blood cells within the thrombus. After adjusting for confounders, the diffuse platelet pattern independently predicted major adverse cardiovascular events, including mortality and stroke recurrence. Subgroup analysis also demonstrated that the association between the diffuse platelet pattern and major adverse cardiovascular events was consistent across key clinical subgroups based on age (≥65 vs. <65 yr), atrial fibrillation, cancer status, and discharge medications. Conclusions Thrombus histology could provide predictive value for long-term prognosis. In particular, histological distribution patterns may be more important than simple composition in thrombus research, including in the prediction of prognosis.

Background: An international reference measurement laboratory network for creatinine (Cr) is lacking; therefore, Korea developed an independent evaluation and certification system. The in vitro diagnostics (IVD) certification program, launched in 2017, formed part of a broader Cr standardization initiative intended to enhance accuracy at the manufacturing stage. Methods: The program was designed to evaluate analytical systems, including all reagent lots, calibrators, and instrument models, twice annually. Bias, imprecision, total error (TE), and linearity were evaluated based on established acceptance criteria. A post-certification process allows submission for a second challenge and validation of corrective actions. Results: Between 2017 and 2023, 489 analytical systems were evaluated. Average acceptance rates for bias, imprecision, TE, and linearity were 70.8%, 95.9%, 87.7%, and 87.8%, respectively. The lowest acceptance rate for bias evaluation was 8.7% for the kinetic Jaffe method without compensation in 2018. Over the 7-year period, the mean absolute percentage bias (absBias%), coefficient of variation (CV), and TE were 4.62%, 1.37%,and 7.29%, respectively. The highest absBias% (7.94%) was observed in the 0.0 ≤ Cr < 1.0target value range. Since 2019, a consistent reduction in absBias% has been observed. Conclusions This program is a pioneering response to the absence of a global certification program for Cr assays. It offers significant advantages, including comprehensive evaluations, fee-free participation, and a robust post-certification process. Continuous participation and improvement efforts by manufacturers have contributed to enhanced accuracy in Cr assays.

Activating mutations in the epidermal growth factor receptor (EGFR) gene, particularly in the tyrosine kinase domain, occur in approximately 20% of non-small cell lung cancer (NSCLC) cases. These mutations, commonly found as deletions in exon 19 or the L858R mutation in exon 21, are crucial targets for EGFR tyrosine kinase inhibitors (TKIs). The third-generation EGFR TKI, osimertinib (TAGRISSO; AstraZeneca, UK), is effective against tumors with the T790M mutation and a liquid biopsy test has been approved by the US Food and Drug Administration as a companion diagnostic for TAGRISSO.This test is now widely implemented in various countries, including South Korea. To ensure high-quality testing, the Korean Association of External Quality Assessment Service launched a liquid biopsy EGFR proficiency testing program in 2017. This study analyzed the results of this program for 2017–2023. The number of participating laboratories increased from three in 2017 to 30 in 2023. All participating laboratories reported results using the Cobas z 480 analyzer (Roche Diagnostics, Germany). The accuracy of the test results was high with 100% correctness in several trials. However, errors were reported in some trials with false positives (e.g., detecting mutations in mutation-free samples) being more common than false negatives. This study evaluated Korean clinical laboratory performance when undertaking liquid biopsies for EGFR mutations. Continuous participation in the external quality assessment program helps laboratories maintain and improve the quality of liquid biopsy EGFR testing, ultimately benefiting patient care by ensuring accurate and reliable mutation detection.

Next-generation sequencing (NGS)-based liquid biopsy using peripheral blood offers a minimally invasive approach to detect tumor-derived circulating tumor DNA (ctDNA). Given the low abundance of ctDNA, accurate analysis is crucial, necessitating external quality assessments.Since 2020, the Korean Association of External Quality Assessment Service has conducted proficiency testing for NGS-based liquid biopsy. This study reviews the proficiency testing results from 2020 to 2023. The program was conducted biannually. Specimens were created by spiking fragmented DNA into fresh frozen plasma to simulate actual clinical samples. The number of target genes reported increased from 5 in 2020 to 17 in 2023. Results were assessed based on concordance with those obtained from targeted NGS panel testing performed before shipping the manufactured specimens.Participating laboratories used various NGS instruments and reagents. The read depth for each genetic variant varied across laboratories, while the reported read percentage of detected variants was generally consistent.Most laboratories accurately reported variants; however, some discrepancies related to variant position descriptions or incorrect reference sequence transcripts were noted. This study evaluates the performance of Korean clinical laboratories in NGS-based liquid biopsy. Continued vigilance in result reporting is necessary, and ongoing external quality assessments can enhance the reliability of NGS-based liquid biopsy testing.

Background: and Purpose The influence of imaging features of brain frailty on outcomes were investigated in acute ischemic stroke patients with minor symptoms and large-vessel occlusion (LVO). Methods: This was a retrospective analysis of a prospective, multicenter, nationwide registry of consecutive patients with acute (within 24 h) minor (National Institutes of Health Stroke Scale score=0–5) ischemic stroke with anterior circulation LVO (acute minor LVO). Brain frailty was stratified according to the presence of an advanced white-matter hyperintensity (WMH) (Fazekas grade 2 or 3), silent/old brain infarct, or cerebral microbleeds. The primary outcome was a composite of stroke, myocardial infarction, and all-cause mortality within 1 year. Results: In total, 1,067 patients (age=67.2±13.1 years [mean±SD], 61.3% males) were analyzed. The proportions of patients according to the numbers of brain frailty burdens were as follows: no burden in 49.2%, one burden in 30.0%, two burdens in 17.3%, and three burdens in 3.5%. In the Cox proportional-hazards analysis, the presence of more brain frailty burdens was associated with a higher risk of 1-year primary outcomes, but after adjusting for clinically relevant variables there were no significant associations between burdens of brain frailty and 1-year vascular outcomes. For individual components of brain frailty, an advanced WMH was independently associated with an increased risk of 1-year primary outcomes (adjusted hazard ratio [aHR]=1.33, 95% confidence interval [CI]=1.03–1.71) and stroke (aHR=1.32, 95% CI=1.00–1.75). Conclusions The baseline imaging markers of brain frailty were common in acute minor ischemic stroke patients with LVO. An advanced WMH was the only frailty marker associated with an increased risk of vascular events. Further research is needed into the association between brain frailty and prognosis in patients with acute minor LVO.

Activating mutations in the epidermal growth factor receptor (EGFR) gene, particularly in the tyrosine kinase domain, occur in approximately 20% of non-small cell lung cancer (NSCLC) cases. These mutations, commonly found as deletions in exon 19 or the L858R mutation in exon 21, are crucial targets for EGFR tyrosine kinase inhibitors (TKIs). The third-generation EGFR TKI, osimertinib (TAGRISSO; AstraZeneca, UK), is effective against tumors with the T790M mutation and a liquid biopsy test has been approved by the US Food and Drug Administration as a companion diagnostic for TAGRISSO.This test is now widely implemented in various countries, including South Korea. To ensure high-quality testing, the Korean Association of External Quality Assessment Service launched a liquid biopsy EGFR proficiency testing program in 2017. This study analyzed the results of this program for 2017–2023. The number of participating laboratories increased from three in 2017 to 30 in 2023. All participating laboratories reported results using the Cobas z 480 analyzer (Roche Diagnostics, Germany). The accuracy of the test results was high with 100% correctness in several trials. However, errors were reported in some trials with false positives (e.g., detecting mutations in mutation-free samples) being more common than false negatives. This study evaluated Korean clinical laboratory performance when undertaking liquid biopsies for EGFR mutations. Continuous participation in the external quality assessment program helps laboratories maintain and improve the quality of liquid biopsy EGFR testing, ultimately benefiting patient care by ensuring accurate and reliable mutation detection.